Michela Rondoni

List of Publications by Year
in descending order

85	1,539	331670 21	315739 38
papers	citations	h-index	g-index

86	86	86	1875
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRÂ-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 2007, 92, 1173-1179.	3.5	198
2	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRAâ€“positive chronic eosinophilic leukemia. Blood, 2007, 109, 4635-4640.	1.4	195
3	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica, 2007, 92, 401-404.	3.5	172
4	Characteristics and outcome of therapyâ€related myeloid neoplasms: Report from the <scp>I</scp>talian network on secondary leukemias. American Journal of Hematology, 2015, 90, E80-5.	4.1	93
5	Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. Leukemia and Lymphoma, 2004, 45, 1791-1795.	1.3	67
6	Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosomeâ€“Positive Leukemia. Journal of Clinical Oncology, 2006, 24, e51-e52.	1.6	61
7	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. American Journal of Hematology, 2016, 91, 692-699.	4.1	54
8	Advanced mast cell disease: an Italian Hematological Multicenter experience. International Journal of Hematology, 2008, 88, 483-488.	1.6	44
9	First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leukemia Research, 2004, 28, 987-990.	0.8	43
10	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology, 2005, 131, 172-179.	2.5	43
11	CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults. Cancers, 2020, 12, 303.	3.7	42
12	Mast cell leukemia: a report of ten cases. Annals of Hematology, 2008, 87, 505-508.	1.8	41
13	Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncology, The, 2007, 8, 273-274.	10.7	39
14	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. Leukemia, 2018, 32, 139-148.	7.2	28
15	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer Journal, 2020, 10, 96.	6.2	28
16	Complete molecular response in CML after p210 BCRâ€“ABL1-derived peptide vaccination. Nature Reviews Clinical Oncology, 2010, 7, 600-603.	27.6	26
17	Realâ€world experience with decitabine as a firstâ€line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. Hematological Oncology, 2019, 37, 447-455.	1.7	25
18	Rapid Detection of Flt3 Mutations in Acute Myeloid Leukemia Patients by Denaturing HPLC. Clinical Chemistry, 2003, 49, 1642-1650.	3.2	24

#	Article	IF	Citations
19	Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. Leukemia and Lymphoma, 2006, 47, 469-472.	1.3	24
20	Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation. Leukemia and Lymphoma, 2004, 45, 731-733.	1.3	23
21	Imatinib mesylate in the treatment of hematologic malignancies. Expert Opinion on Biological Therapy, 2007, 7, 1597-1611.	3.1	23
22	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia, 2007, 21, 1442-1450.	7.2	22
23	Systematic Evaluation of Hypereosinophilic Syndrome-Related Organ Damage According to FIP1L1-PDGFRA Status and Response to the Therapy: Analysis from Prospective Clinical Trial with Imatinib Mesylate.. Blood, 2007, 110, 3557-3557.	1.4	21
24	Hypereosinophilic Syndrome and Molecularly Targeted Therapy. Seminars in Hematology, 2007, 44, S4-S16.	3.4	17
25	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. Blood, 2006, 108, 836-836.	1.4	17
26	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.. Haematologica, 2007, 92, 1721-1722.	3.5	15
27	Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. Expert Opinion on Biological Therapy, 2006, 6, 1011-1022.	3.1	12
28	Imatinib mesylate in the treatment of c-kitâ€“positive acute myeloid leukemia: is this the real target?. Blood, 2005, 105, 904-905.	1.4	9
29	A rare case of Hemoglobin Leiden interfering with the DIFF channel of Sysmex XE-2100. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 436-437.	1.2	9
30	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncology, 2018, 14, 2713-2723.	2.4	9
31	Long-term molecular complete remission with IFN-Î± in Ph+ adult acute lymphoid leukemia patients. Leukemia, 2008, 22, 1617-1618.	7.2	8
32	The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. Haematologica, 2004, 89, 1269-71.	3.5	8
33	Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.. Blood, 2007, 110, 322-322.	1.4	7
34	Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5qâ€•deletion. British Journal of Haematology, 2010, 148, 483-484.	2.5	6
35	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. British Journal of Haematology, 2021, 193, 845-848.	2.5	6
36	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. Biomedicines, 2021, 9, 388.	3.2	6

#	Article	IF	Citations
37	Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 684396.	2.8	6
38	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. Cell Biology and Toxicology, 2023, 39, 795-811.	5.3	6
39	Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.. Blood, 2005, 106, 1857-1857.	1.4	6
40	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. Blood, 2009, 114, 648-648.	1.4	6
41	Serendipitous detection of Hemoglobin G-Ferrara variant with Sysmex DIFF channel. Clinical Biochemistry, 2016, 49, 192-193.	1.9	5
42	Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation.. Blood, 2007, 110, 3562-3562.	1.4	5
43	PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. Cancer Chemotherapy and Pharmacology, 2008, 61, 713-716.	2.3	4
44	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. Minerva Medica, 2020, 111, 478-490.	0.9	4
45	Prompt Resolution of Nasal Aspergillosis with Intra-Nasal Instillation of Liposomal Amphotericin-B (AmbisomeÂ®) and Granulocyte Transfusions. Leukemia and Lymphoma, 2004, 45, 637-638.	1.3	3
46	Rearrangements of ATP5Lâ€KMT2A in acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 192, e139-e144.	2.5	3
47	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. Blood, 2018, 132, 789-789.	1.4	3
48	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. Blood, 2005, 106, 375-375.	1.4	3
49	Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. European Journal of Haematology, 2004, 72, 302-303.	2.2	2
50	Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients. Blood, 2019, 134, 1363-1363.	1.4	2
51	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. Blood, 2010, 116, 3413-3413.	1.4	2
52	The New Italian Mastocytosis Registry.. Blood, 2010, 116, 3805-3805.	1.4	2
53	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. Blood, 2014, 124, 1881-1881.	1.4	2
54	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. Blood, 2015, 126, 4085-4085.	1.4	2

#	Article	IF	Citations
55	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 151, 85-86.	1.0	1
56	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. Blood, 2004, 104, 1507-1507.	1.4	1
57	Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.. Blood, 2008, 112, 2118-2118.	1.4	1
58	Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow â€“up of 30 to 92 Months.. Blood, 2009, 114, 3894-3894.	1.4	1
59	Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL).. Blood, 2009, 114, 167-167.	1.4	1
60	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. Blood, 2016, 128, 3136-3136.	1.4	1
61	MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. Blood, 2018, 132, 1779-1779.	1.4	1
62	CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. Blood, 2021, 138, 1262-1262.	1.4	1
63	Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia. Cancer Genetics and Cytogenetics, 2010, 197, 84-85.	1.0	0
64	Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib. Leukemia Research, 2010, 34, e215-e216.	0.8	0
65	A der(1)t(1;21)(p36.3;q22) in a Patient with Acute Myelogenous Leukemia M2. Acta Haematologica, 2010, 124, 44-45.	1.4	0
66	MDS-227: Digital PCR for Sensitive Detection and Accurate Quantification of KIT D816V Allele Burden in Patients with Suspected Systemic Mastocytosis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S320.	0.4	0
67	MPN-204: Midostaurin Synergizes with Nilotinib and Dasatinib Restoring SETD2 Expression and Activity in Advanced Systemic Mastocytosis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S334.	0.4	0
68	MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S356-S357.	0.4	0
69	Poster: MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S233.	0.4	0
70	Efficacy and Toxicity of FLAI-G-CSF and Mylotarg for Induction/Consolidation of AML Patients, Not Treatable with Conventional Chemotherapy.. Blood, 2004, 104, 4514-4514.	1.4	0
71	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. Blood, 2006, 108, 2016-2016.	1.4	0
72	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. Blood, 2006, 108, 2017-2017.	1.4	0

#	Article	IF	Citations
73	Two Novel WT-1 Derived Peptides Induce CD4+ peptideâ€“specific T Cell Proliferation in Patients with Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 5432-5432.	1.4	0
74	Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up.. Blood, 2008, 112, 941-941.	1.4	0
75	Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study. Blood, 2008, 112, 5223-5223.	1.4	0
76	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.. Blood, 2009, 114, 4147-4147.	1.4	0
77	Abstract 656: High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL). , 2010, , .		0
78	RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase I-II Preliminary Results. Blood, 2010, 116, 4359-4359.	1.4	0
79	Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up. Blood, 2010, 116, 1986-1986.	1.4	0
80	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. Blood, 2013, 122, 2659-2659.	1.4	0
81	PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.. Journal of Clinical Oncology, 2014, 32, 7113-7113.	1.6	0
82	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. Blood, 2014, 124, 1856-1856.	1.4	0
83	A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. Blood, 2014, 124, 3188-3188.	1.4	0
84	Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene. , 2015, , .		0
85	In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors. Blood, 2019, 134, 4204-4204.	1.4	0